What is HC Wainwright’s Forecast for PLX Q1 Earnings?

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for shares of Protalix BioTherapeutics in a research report issued on Monday, February 3rd. HC Wainwright analyst R. Selvaraju anticipates that the company will earn $0.03 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.06 EPS.

Separately, StockNews.com lowered shares of Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday.

Protalix BioTherapeutics Trading Up 6.0 %

PLX opened at $2.67 on Tuesday. Protalix BioTherapeutics has a 12 month low of $0.82 and a 12 month high of $2.71. The company has a market cap of $196.59 million, a PE ratio of -20.54 and a beta of 0.75. The company has a 50 day moving average of $2.01 and a 200 day moving average of $1.43.

Hedge Funds Weigh In On Protalix BioTherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC purchased a new position in shares of Protalix BioTherapeutics in the second quarter valued at about $37,000. Squarepoint Ops LLC grew its stake in shares of Protalix BioTherapeutics by 673.3% in the second quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock worth $161,000 after purchasing an additional 119,949 shares during the last quarter. AQR Capital Management LLC purchased a new position in Protalix BioTherapeutics during the 2nd quarter valued at about $67,000. GSA Capital Partners LLP raised its position in Protalix BioTherapeutics by 8.5% during the 3rd quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock valued at $444,000 after purchasing an additional 33,969 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Protalix BioTherapeutics in the 3rd quarter worth approximately $36,000. 16.53% of the stock is currently owned by institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.